Skip to main content

Research Repository

Advanced Search

Guidance On The Use Of Esketamine Nasal Spray For Treatment Resistant Depression

White, Jacquie; Feetam, Celia


Celia Feetam


This guidance was commissioned by Janssen-Cilag Ltd as part of an extensive programme of work to support practitioners across the UK to apply best practice to the supervised self-administration of esketamine nasal spray. The document was generated without input from Janssen-Cilag Ltd and the company had no editorial control over the content. Approval prior to publication on the Janssen Medical Cloud was granted following medical (peer) review by Janssen's parent company Johnson and Johnson.


White, J., & Feetam, C. (2021). Guidance On The Use Of Esketamine Nasal Spray For Treatment Resistant Depression. Janssen Medical Cloud for UK Healthcare Professionals

Other Type Manual / Guide
Acceptance Date Apr 1, 2021
Online Publication Date Apr 1, 2021
Publication Date 2021
Deposit Date May 20, 2021
Publicly Available Date Oct 27, 2022
Pages 95
Keywords Clinical guideline, medicines management, pharmacology, intranasal administration, major depressive disorder
Public URL
Additional Information This is a knowledge exchange output for a novel antidepressant that is administered via the intranasal route (antidepressants are traditionally administered by the oral route) . Intranasal administration is a route of administration where a medicine is insufflated through the nose. Whilst this route of medicine delivery is not uncommon in other therapeutic areas, esketamine nasal spray is the first medicine to be available for intranasal administration for the treatment of a mental illness. Co-authored with a Specialist Mental Health Pharmacist the document is intended to provide guidance for prescribers and other healthcare professionals (HCPs) on the correct use of this novel treatment in practice.